BLA for subcutaneous form of LEQEMBI accepted in China, could be first anti-amyloid treatment with at-home injection.
Pending approval, lecanemab has the potential to be the initial and solitary anti-amyloid therapy in China providing at-home injections from the start of treatment for this advancing and persistent ailment. This development could lead to groundbreaking progress in the country's healthcare system for managing such conditions.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments